Bosentan Tablet, For Suspension
Product Images NDC 68180-340

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Bosentan (NDC 68180-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bosentan-carton (Bosentan 32mg 4x14 Unit Dose)

Bosentan-carton (Bosentan 32mg 4x14 Unit Dose)
This text is a detailed description of a medication labeled as "L ETRET" for Oral Suspension tablets. It includes information about phenylketonurics, proper storage conditions, recommended dosage, and instructions for dispensing to patients. The medication guide must be given to each patient along with the prescription. The tablets contain Phenylalanine at 1.85 mg per tablet. It is recommended to disperse the tablets in water before administration and store them at a specific temperature range. Additionally, it mentions the manufacturer and distributor information related to the medication.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
This text provides a list of interacting drugs and recommendations related to their use. It includes names such as Cyclosporin A, Glibenclamide, Simvastatin, Hydroxy acid simvastatin, Norethindrone, and others. The recommendations advise caution in medication usage, monitoring cholesterol levels, and the use of additional contraception.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
This is a list of interacting drugs and their effects on other medications. It includes information on Gycosporin A, Lopinavirirtonavic, Rifampin, and their impacts on Ctrough, Gmax, Auc, Cmax, and Foid-2. Recommendations such as contraindication, dose reduction, and frequency of monitoring (e.g., AST/ALT weekly) are provided.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This text contains information regarding drug interactions and the induction of specific enzymes such as CYP3A. It also mentions the interaction with different medications and the recommendations for monitoring and adjustment of dosages to avoid adverse effects. Overall, it provides guidance on potential drug interactions and necessary precautions to be taken while using these medications.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text provides information on drug interactions involving medications like Cyclosporin A, Lopinavir/ritonavir, Rifampin, Ketoconazole, Losartan, and others. It includes details on enzyme inhibition and induction, substrates, and recommendations such as contraindication, dose reduction, and monitoring. The text also mentions specific enzymes like CYP3A and provides pharmacokinetic parameters like Cmax, AUC, and trough levels.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
This is a data table showing results over time for a study involving Bosentan and Placebo. The table includes percentages and time in weeks. The specific data points are not clearly listed.*
FDA Label Image

Figure-1 (Split Tablet Images)

Figure-1 (Split Tablet Images)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.